Machine learning-driven multi-targeted drug discovery in colon cancer using biomarker signatures
Abstract Computational oncology advances multi-targeted therapies for Colon Cancer (CC) by leveraging molecular data and identifying potential drug candidates. However, challenges persist in understanding CC molecular pathways and identifying essential genes. This research integrates biomarker signa...
Saved in:
| Main Authors: | Tingting Liu, Lifan Zhong, Xizhe Sun, Zhijiang He, Witiao Lv, Liyun Deng, Yanfei Chen |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-08-01
|
| Series: | npj Precision Oncology |
| Online Access: | https://doi.org/10.1038/s41698-025-01058-6 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Characterization of the Active Ingredients and Prediction of the Potential Anticolitis Mechanism of the Feng-Liao-Chang-Wei-Kang Capsule via Mass Spectrometry and Network Pharmacology
by: Tingting Liu, et al.
Published: (2025-01-01) -
Advanced organoid models for targeting Kras-driven lung adenocarcinoma in drug discovery and combination therapy
by: İsa Taş, et al.
Published: (2025-04-01) -
AI-Driven Drug Discovery: A Comprehensive Review
by: Fábio J. N. Ferreira, et al.
Published: (2025-06-01) -
Oxidative stress gene expression in ulcerative colitis: implications for colon cancer biomarker discovery
by: Ting Yan, et al.
Published: (2025-07-01) -
A migrasome-related lncRNA signature predicts prognosis and immune response in hepatocellular carcinoma: Implications for biomarker discovery and therapeutic targeting
by: Haotian Qin, et al.
Published: (2025-08-01)